Matthew R Starr1, Lauren A Dalvin1, Jackson E AbouChehade1, Gena M Damento2, Maria Garcia1, Saumya M Shah1, David O Hodge3, Raymond Iezzi4, Sophie J Bakri5. 1. Department of Ophthalmology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Mayo Clinic School of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 3. Department of Health Sciences Research/Biomedical Statistics and Informatics, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA. 4. Department of Ophthalmology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. iezzi.raymond@mayo.edu. 5. Department of Ophthalmology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. bakri.sophie@mayo.edu.
Abstract
PURPOSE: The purpose of this study is to compare the use of metformin in patients with both exudative and non-exudative age-related macular degeneration (AMD) versus control populations. DESIGN: Retrospective review of three age- and sex-matched cohorts from 1/1/2004 to 12/31/2013: patients with exudative AMD, a cohort of dry AMD patients, and a cohort of patients without AMD. The primary endpoint was the incidence of metformin use in all of the cohorts. RESULTS: There were 1512 patients, with 504 in each of the three cohorts. There was no difference in the prevalence of diabetes between cohorts. Compared to patients with dry AMD, patients with no AMD had increased likelihood of metformin use (p = 0.0168, OR 1.66 (1.09-2.51). There was no difference in the likelihood of metformin use between exudative AMD patients and non-AMD controls. CONCLUSIONS: There appears to be an increased incidence of metformin use in patients without AMD compared to patients with dry AMD. Metformin's current role in the treatment of anti-aging diseases makes it a plausible target for use in the treatment of AMD, particularly dry AMD.
PURPOSE: The purpose of this study is to compare the use of metformin in patients with both exudative and non-exudative age-related macular degeneration (AMD) versus control populations. DESIGN: Retrospective review of three age- and sex-matched cohorts from 1/1/2004 to 12/31/2013: patients with exudative AMD, a cohort of dry AMD patients, and a cohort of patients without AMD. The primary endpoint was the incidence of metformin use in all of the cohorts. RESULTS: There were 1512 patients, with 504 in each of the three cohorts. There was no difference in the prevalence of diabetes between cohorts. Compared to patients with dry AMD, patients with no AMD had increased likelihood of metformin use (p = 0.0168, OR 1.66 (1.09-2.51). There was no difference in the likelihood of metformin use between exudative AMD patients and non-AMD controls. CONCLUSIONS: There appears to be an increased incidence of metformin use in patients without AMD compared to patients with dry AMD. Metformin's current role in the treatment of anti-aging diseases makes it a plausible target for use in the treatment of AMD, particularly dry AMD.
Authors: Hsien-Chang Lin; Joshua D Stein; Bin Nan; David Childers; Paula Anne Newman-Casey; Debra A Thompson; Julia E Richards Journal: JAMA Ophthalmol Date: 2015-08 Impact factor: 7.389
Authors: Emily E Brown; Jacob D Ball; Zhaoyi Chen; Gibran S Khurshid; Mattia Prosperi; John D Ash Journal: Invest Ophthalmol Vis Sci Date: 2019-04-01 Impact factor: 4.799